Filed: Herewith

## In the claims:

Please cancel Claims 1-38 without prejudice or disclaimer.

Please add new Claims 39-58 as follows.

(New) An isolated nucleic acid having at least 80% nucleic acid sequence identity

to:


- a nucleic acid sequence encoding the polypeptide shown in Figure 118 (SEQ ID (a) NO:339);
- a nucleic acid sequence encoding the polypeptide shown in Figure 118 (SEQ ID (b) NO:339), lacking its associated signal peptide;
- a nucleic acid sequence encoding the extracellular domain of the polypeptide shown (c) in Figure 118 (SEQ ID NO:339);
- a nucleic acid sequence encoding the extracellular domain of the polypeptide shown (d) in Figure 118 (SEQ ID NO:339), lacking its associated signal peptide;
  - the nucleic acid sequence shown in Figure 117 (SEQ ID NO:338); (e)
- the full-length coding sequence of the nucleic acid sequence shown in Figure 117 (f) (SEQ ID NO:338); or
- the full-length coding sequence of the cDNA deposited under ATCC accession (g) number 209490.
- (New) The isolated nucleic acid of Claim 39 having at least 85% nucleic acid 40. sequence identity to:
- a nucleic acid sequence encoding the polypertide shown in Figure 118 (SEQ ID (a) NO:339);
- a nucleic acid sequence encoding the polypeptide shown in Figure 118 (SEQ ID (b) NO:339), lacking its associated signal peptide;

Filed: Herewith

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 118 (SEQ ID NO:339);

a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 118 (SEQ ID NO:339), lacking its associated signal peptide;

- (e) the nucleic acid sequence shown in Figure 117 (SEQ ID NO:338);
- (f) the full-length coding sequence of the nucleic acid sequence shown in Figure 117 (SEQ ID NO:338); or
- (g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209490.
- 41. (New) The isolated nucleic acid of Claim 39 having at least 90% nucleic acid sequence identity to:
- (a) a nucleic acid sequence encoding the polypeptide shown in Figure 118 (SEQ ID NO:339);
- (b) a nucleic acid sequence encoding the polypeptide shown in Figure 118 (SEQ ID NO:339), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 118 (SEQ ID NO:339);
- (d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 118 (SEQ ID NO:339), lacking its associated signal peptide;
  - (e) the nucleic acid sequence shown in Figure 117 (SEQ ID NO:338);
- (f) the full-length coding sequence of the nucleic acid sequence shown in Figure 117 (SEQ ID NO:338); or
- (g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209490.



Filed: Herewith

42. (New) The isolated nucleic acid of Claim 39 having at least 95% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 118 (SEQ ID NO:339);

- (b) a nucleic acid sequence encoding the polypeptide shown in Figure 118 (SEQ ID NO:339), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 118 (SEQ ID NO:339);
- (d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 118 (SEQ ID NO 339), lacking its associated signal peptide;
  - (e) the nucleic acrd sequence shown in Figure 117 (SEQ ID NO:338);
- (f) the full-length coding sequence of the nucleic acid sequence shown in Figure 117 (SEQ ID NO:338); or
- (g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209490.
- 43. (New) The isolated nucleic acid of Claim 39 having at least 99% nucleic acid sequence identity to:
- (a) a nucleic acid sequence encoding the polypeptide shown in Figure 118 (SEQ ID NO:339);
- (b) a nucleic acid sequence encoding the polypeptide shown in Figure 118 (SEQ ID NO:339), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 118 (SEQ ID NO:339);
- (d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 118 (SEQ ID NO:339), lacking its associated signal peptide;

Filed: Herewith

the nucleic acid sequence shown in Figure 117 (SEQ ID NO:338);

(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 117 (SEQ ID NO:338); or

(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209490.

44. (New) An isolated nucleic acid comprising:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 118 (SEQ ID NO:339);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 118 (SEQ ID NO:339), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 118 (SEQ ID NO:339);

(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 118 (SEQ ID NO:339), lacking its associated signal peptide;

(e) the nucleic acid sequence shown in Figure 117 (SEQ ID NO:338);

(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 117 (SEQ ID NO:338); or

(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209490.

45. (New) The isolated nucleic acid of Claim 44 comprising a nucleic acid sequence encoding the polypeptide shown in Figure 118 (SEQ ID NO:339).

A IDDIDEL BY45

Serial No.: Not yet assigned

Filed: Herewith

46. (New) The isolated nucleic acid of Claim 44 comprising a nucleic acid sequence encoding the polypeptide shown in Figure 118 (SEQ ID NO:339), lacking its associated signal peptide.

47. (New) The isolated nucleic acid of Claim 44 comprising a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 118 (SEQ ID NO:339).

48. (New) The isolated nucleic acid of Claim 44 comprising a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 118 (SEQ ID NO:339), lacking its associated signal peptide.

49. (New) The isolated nucleic acid of Claim 44 comprising the nucleic acid sequence shown in Figure 117 (SEQ ID NO:338).

50. (New) The isolated nucleic acid of Claim 44 comprising the full-length coding sequence of the nucleic acid sequence shown in Figure 117 (SEQ ID NO:338).

51. (New) The isolated nucleic acid of Claim 44 comprising the full-length coding sequence of the cDNA deposited under ATCC accession number 209490.

§2. (New) An isolated nucleic acid that hybridizes to:

a nucleic acid sequence encoding the polypeptide shown in Figure 118 (SEQ ID

NO:339);


(b) a nucleic acid sequence encoding the polypeptide shown in Figure 118 (SEQ ID NO:339), lacking its associated signal peptide;

Filed: Herewith

a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 1\( 8 \) (SEQ ID NO:339);

(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 118 (SEQ ID NO:339), lacking its associated signal peptide;

- (e) the nucleic acid sequence shown in Figure 117 (SEQ ID NO:338);
- (f) the full-length coding sequence of the nucleic acid sequence shown in Figure 117 (SEQ ID NO:338); or
- (g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209490.
- 53. (New) The isolated nucleic acid of Claim 52, wherein said hybridization occurs under stringent conditions.
- 54. (New) The isolated nucleic acid of Claim 52 which is at least 10 nucleotides in length.
  - 55. (New) A vector comprising the nucleic acid of Claim 39.
- 56. (New) The vector of Claim 55, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.
  - 57. (New) A host cell comprising the vector of Claim 55.
- 58. (New) The host cell of Claim 57, wherein said cell is a CHO cell, an *E. coli* or a yeast cell.--



Filed: Herewith

PATENT TRADEMARK OFFICE

Applicants respectfully request entry of these new claims for prosecution in this application. The Examiner is invited to contact the undersigned at (650) 225-4461 if any issues may be resolved in that manner.

Respectfully submitted,

GENENTECH, INC.

Mark T. Kresnak, Ph.D.

Reg. No. 42,767

Telephone: (650) 225-4461

-8-